001     305417
005     20251020115507.0
024 7 _ |a 10.1172/JCI187627
|2 doi
024 7 _ |a pmid:41100815
|2 pmid
024 7 _ |a 0021-9738
|2 ISSN
024 7 _ |a 1558-8238
|2 ISSN
037 _ _ |a DKFZ-2025-02146
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Funk, Cornelius
|0 P:(DE-He78)0921630050b802a96db645029b1a982b
|b 0
|e First author
|u dkfz
245 _ _ |a High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma.
260 _ _ |a Ann Arbor, Mich.
|c 2025
|b ASCJ
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1760949612_1189493
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B410#LA:B410# / epub
520 _ _ |a Chromosome 8 (chr8) gains are common in cancer, but their contribution to tumor heterogeneity is largely unexplored. Ewing sarcoma (EwS) is defined by FET::ETS fusions with few other recurrent mutations to explain clinical diversity. In EwS, chr8 gains are the second most frequent alteration, making it an ideal model to study their relevance in an otherwise silent genomic context. We report that chr8 gain-driven expression patterns correlate with poor overall survival of EwS patients. This effect is mainly mediated by increased expression of the translation initiation factor binding protein 4E-BP1, encoded by EIF4EBP1 on chr8. Among all chr8-encoded genes, EIF4EBP1 expression showed the strongest association with poor survival and correlated with chr8 gains in EwS tumors. Similar findings emerged across multiple TCGA cancer entities. Multi-omics profiling revealed that 4E-BP1 orchestrates a pro-proliferative proteomic network. Silencing 4E-BP1 reduced proliferation, clonogenicity, spheroidal growth in vitro, and tumor growth in vivo. Drug screens demonstrated that high 4E-BP1 expression sensitizes EwS to pharmacological CDK4/6-inhibition. Chr8 gains and elevated 4E-BP1 emerge as prognostic biomarkers in EwS, with poor outcomes driven by 4E-BP1-mediated pro-proliferative networks that sensitize tumors to CDK4/6 inhibitors. Testing for chr8 gains may enhance risk stratification and therapy in EwS and other cancers.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Cancer
|2 Other
650 _ 7 |a Genetic variation
|2 Other
650 _ 7 |a Genetics
|2 Other
650 _ 7 |a Mouse models
|2 Other
650 _ 7 |a Oncology
|2 Other
700 1 _ |a Ehlers, Anna
|0 P:(DE-He78)9b3d0cef2b1553fc9d2c5f24d91c12e1
|b 1
|e First author
|u dkfz
700 1 _ |a Orth, Martin F
|b 2
700 1 _ |a Aljakouch, Karim
|0 P:(DE-He78)c51d9cafe6d7e6e3c91b299ed8014858
|b 3
|u dkfz
700 1 _ |a Li, Jing
|0 P:(DE-He78)b37e68255201ee3a776f69fd2462a099
|b 4
|u dkfz
700 1 _ |a Hoelting, Tilman Lb
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Will, Rainer
|0 P:(DE-He78)18218139eec55d83cf82679934e5cd75
|b 6
|u dkfz
700 1 _ |a Geyer, Florian H
|0 P:(DE-He78)824510670ec489266e6e294c4f8b0e6c
|b 7
|u dkfz
700 1 _ |a Ceranski, A Katharina
|0 P:(DE-He78)4f8b6ddd5c9a7b08d3d59c5f7e275cf9
|b 8
|u dkfz
700 1 _ |a Willis, Franziska
|b 9
700 1 _ |a Vinca, Endrit
|0 P:(DE-He78)a46733606e787aeb59c33d2a642d02d7
|b 10
700 1 _ |a Ohmura, Shunya
|0 P:(DE-He78)c25b54b0c834093d1f884d2615e305d6
|b 11
|u dkfz
700 1 _ |a Imle, Roland
|0 P:(DE-He78)3c021852cf94cb29825e65baa82ed54b
|b 12
|u dkfz
700 1 _ |a Siebenlist, Jana
|0 P:(DE-He78)a804dfb61b29a00e81bb457c172efce3
|b 13
700 1 _ |a Yershova, Angelina
|0 P:(DE-He78)f55d074b17fca49f1c411dfae4d30a93
|b 14
|u dkfz
700 1 _ |a Knott, Maximilian Ml
|b 15
700 1 _ |a Zahnow, Felina
|0 P:(DE-He78)ec64d75fe6aad968b3981bc1c1529f72
|b 16
|u dkfz
700 1 _ |a Sastre, Ana
|b 17
700 1 _ |a Alonso, Javier
|b 18
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 19
|u dkfz
700 1 _ |a Peterziel, Heike
|b 20
700 1 _ |a Loboda, Anna
|b 21
700 1 _ |a Schneider, Martin
|b 22
700 1 _ |a Banito, Ana
|0 P:(DE-He78)990de6ec6c2f0a40b17ed75162ca19e8
|b 23
|u dkfz
700 1 _ |a Leprivier, Gabriel
|b 24
700 1 _ |a Hartmann, Wolfgang
|b 25
700 1 _ |a Dirksen, Uta
|b 26
700 1 _ |a Witt, Olaf
|0 P:(DE-He78)143af26de9d57bf624771616318aaf7c
|b 27
|u dkfz
700 1 _ |a Oehme, Ina
|0 P:(DE-He78)908367a659dea9e28dac34592b3c46e5
|b 28
|u dkfz
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 29
|u dkfz
700 1 _ |a Romero-Pérez, Laura
|0 P:(DE-HGF)0
|b 30
700 1 _ |a Krijgsveld, Jeroen
|0 P:(DE-He78)939d5891259c638c1ab053b1456a578c
|b 31
|u dkfz
700 1 _ |a Cidre-Aranaz, Florencia
|0 P:(DE-HGF)0
|b 32
700 1 _ |a Grünewald, Thomas
|0 P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c
|b 33
|e Last author
|u dkfz
700 1 _ |a Musa, Julian
|0 P:(DE-He78)476ba475ebb0d48ae4ec27f03d836a41
|b 34
|e Last author
|u dkfz
773 _ _ |a 10.1172/JCI187627
|0 PERI:(DE-600)2018375-6
|p nn
|t The journal of clinical investigation
|v nn
|y 2025
|x 0021-9738
909 C O |o oai:inrepo02.dkfz.de:305417
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)0921630050b802a96db645029b1a982b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)9b3d0cef2b1553fc9d2c5f24d91c12e1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)c51d9cafe6d7e6e3c91b299ed8014858
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)b37e68255201ee3a776f69fd2462a099
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)18218139eec55d83cf82679934e5cd75
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)824510670ec489266e6e294c4f8b0e6c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)4f8b6ddd5c9a7b08d3d59c5f7e275cf9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)a46733606e787aeb59c33d2a642d02d7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)c25b54b0c834093d1f884d2615e305d6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)3c021852cf94cb29825e65baa82ed54b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)a804dfb61b29a00e81bb457c172efce3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)f55d074b17fca49f1c411dfae4d30a93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)ec64d75fe6aad968b3981bc1c1529f72
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)990de6ec6c2f0a40b17ed75162ca19e8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 27
|6 P:(DE-He78)143af26de9d57bf624771616318aaf7c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)908367a659dea9e28dac34592b3c46e5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 29
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 30
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)939d5891259c638c1ab053b1456a578c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 32
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-He78)476ba475ebb0d48ae4ec27f03d836a41
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN INVEST : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-02-16T10:37:49Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-02-16T10:37:49Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2024-02-16T10:37:49Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-02-16T10:37:49Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b J CLIN INVEST : 2022
|d 2024-12-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-27
920 2 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
920 1 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
920 1 _ |0 I:(DE-He78)B230-20160331
|k B230
|l B230 Proteomik von Stammzellen und Krebs
|x 1
920 1 _ |0 I:(DE-He78)W111-20160331
|k W111
|l Zelluläre Tools
|x 2
920 1 _ |0 I:(DE-He78)B380-20160331
|k B380
|l NWG Weichteilsarkome
|x 3
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 4
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 5
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 6
920 0 _ |0 I:(DE-He78)B410-20160331
|k B410
|l Translationale Pädiatrische Sarkomforschung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B410-20160331
980 _ _ |a I:(DE-He78)B230-20160331
980 _ _ |a I:(DE-He78)W111-20160331
980 _ _ |a I:(DE-He78)B380-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21